Name (Synonyms) | Correlation | |
---|---|---|
drug344 | Bicalutamide 150 Mg Oral Tablet Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D000437 | Alcoholism NIH | 0.58 |
D019966 | Substance-Related Disorders NIH | 0.38 |
D004194 | Disease NIH | 0.18 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The purpose of this study is to test the efficacy of a substance use disorder intervention delivered via a mobile application in an adult population during the COVID-19 pandemic. This study that will test the comparative efficacy of the mobile-app based substance use disorder program to reduce substance use relative to a wait list control condition, and explore between group differences on quality of life indices as well as retention and engagement during COVID-19.
Description: Range from 0-100 (no pain to worst pain imaginable)
Measure: Pain rating Time: Difference between baseline and post-treatment (8 weeks from baseline)Description: Total score between 0-27, higher scores indicate greater levels of depression
Measure: Patient Health Questionnaire-9 (PHQ-9) Time: Difference between baseline and post-treatment (8 weeks from baseline)Description: Total score between 0-21, higher scores indicate greater levels of anxiety
Measure: General Anxiety Disorder-7 (GAD-7) Time: Difference between baseline and post-treatment (8 weeks from baseline)Description: Range from 8 to 32, with higher values indicating higher satisfaction
Measure: Client Satisfaction Questionnaire (CSQ) Time: Post-treatment (8 weeks from baseline)